Drug Industry Considers Full Impact Of 2010 Pharmacopeia Edition
This article was originally published in PharmAsia News
Although the 2010 edition of the Chinese pharmacopeia has been released, top priorities have shifted toward helping the drug industry and medical personnel understand its impact
You may also be interested in...
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.